Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 7Ovarian Neoplasms 6Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Vaginal Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

camrelizumab 3pembrolizumab 2apatinib 2Methylprednisolone 2Dactinomycin 2Alemtuzumab 2zimberelimab 1toripalimab 1sargramostim 1dostarlimab 1carotuximab 1aldesleukin 1Tacrolimus 1Specimen Handling 1Prednisone 1Pemetrexed 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-11 1Interferon-alpha 1Injections 1Immunologic Techniques 1Flow Cytometry 1Filgrastim 1CTLA-4 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gestational Trophoblastic Disease × dostarlimab × Clear all
NCT05405192 2023-02-28

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

University of Miami

Phase 2 Withdrawn
Gynecologic

Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡